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Control measures designed to prevent abuse of opioid medicines often unintentionally 
restrict legitimate medical use, leaving millions of patients with cancer in pain. This 
study aimed to develop and validate an assessment instrument based on the WHO 
Policy Guidelines, and subsequently to systematically identify legal and regulatory 
barriers to access to opioids in 11 European countries using this instrument. Relevant 
legislation and regulations were independently reviewed by three reviewers. Potential 
barriers were found in all countries, varying from 22 to 132 per country and varying 
from 1 to 49 per single category. Individual differences in the level of impediment were 
shown (for example: prescription validity ranging between 5 days and 13 weeks). The 
results of this review should give rise to a critical national review and revision of 
provisions that may impede access to opioids in a way that is disproportional to their 





Opioid analgesics are indispensable for the treatment of moderate to severe 
cancer pain.1 The World Health Organization (WHO) has recognised this medical need by 
adding morphine to the ‘WHO Model List of Essential Medicines’:2 medically necessary 
medicines that should be available in sufficient quantity at an affordable price. Despite 
this internationally acknowledged medical need, at least 79% of the world population 
has no or very low to low access to opioid medicines for pain relief.3 The WHO estimates 
that on a global level 5.5 million terminal cancer patients suffer moderate to severe pain 
due to inadequate access to controlled medicines.4 A variety of factors is considered to 
contribute to inadequate access including economic aspects, legislation and policy, lack 
of knowledge and societal attitudes.4–6 The latter three factors are strongly interrelated: 
lack of knowledge and misconceptions about opioids in itself contribute to fear of using 
opioid medicines in medical practice and hence may restrict access to these medicines. 
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Additionally, this misguided fear may cause governments and policy makers to 
implement restrictive policies and legislation. These restrictive policies and legislation in 
turn foster fear of using opioid medicines, in particular if severe sanctions are involved 
for unintended violations of these legislation and policies. As a result of this complex 
interaction of factors influencing access, patients worldwide suffer pain and other 
concomitant clinical consequences that impair the quality of life, such as physical, 
psychosocial and psychological malfunctioning.7 
While other factors as described above are also relevant, legal and regulatory 
control measures are considered to play an important role in the global problem of 
inadequate access.8,9,6,5,10,11,12 Opioid medicines are controlled under the international 
agreement ‘the Single Convention on Narcotic Drugs’.13 Parties to this Single Convention 
on Narcotic Drugs are obliged to take measures to prevent abuse and diversion by 
limiting the use of these controlled medicines to medical and scientific purposes. 
Despite (inter)national control measures, satisfactory levels of prevention of abuse and 
diversion are not always achieved which may result in further control actions.14 In New 
York City for example, in response to a progressive increase in overdose and deaths 
from opioid medicines, clinical guidelines were established limiting the prescribing of 
opioid analgesics in emergency departments to a 3-day treatment period15 and 
excluding the prescribing of some long-acting opioid analgesics.14 These control 
measures may sometimes be necessary to reduce risks associated with abuse and 
diversion, although there is little high quality evidence to support this. In the United 
States for example, strategies focussing on patient and prescriber information showed 
to be useful to (moderately) decrease opioid over-prescribing and diversion.16 However, 
the problems and also the solutions in the United Stated are very specific and are not 
comparable to the situation in many other countries across the world.17 These measures 
may not reduce abuse and diversion in countries where there is no over-prescribing and 
where there is a different mechanism behind abuse and diversion.  
 Although implementation of more strict control measures may result in 
prevention of abuse and diversion, the downside is that legitimate medical use may also 
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be restricted. As a result, access to opioid medicines is inadequate for millions of 
patients that rely on their use including patients with moderate to severe cancer pain. 
Numerous studies have reported on legal and regulatory barriers to access to opioid 
analgesics, mostly in low and middle income countries. Strict control measures were 
considered burdensome and complex and were deemed to interfere with medical 
practice.10 Frequently reported legal and regulatory restrictions to access include the 
requirement for permission to prescribe or receive opioids, limitations on the amount to 
be prescribed, restrictions regarding dispensing privileges and the absence of 
emergency provisions.9,18–21 
 Where on an international level the prevention of abuse and diversion has 
prevailed for decades, more recently this focus has shifted towards ensuring access to 
essential medicines. In this context, governments were urged by the International 
Narcotics Control Board and other international organisations and agencies to critically 
examine their national policies and legislations and remove impediments to the 
adequate availability of opioid medicines for medical and scientific purposes.10,22,23 
Governments that now implement control measures are facing a dilemma in their 
efforts to achieve maximum public health outcome: how to prevent opioid abuse while 
not negatively impacting access to opioid medicines for patients in medical need? 
 An instrument was developed to support government representatives and policy 
makers in evaluating their national policies and legislation: the WHO Policy Guidelines 
‘Ensuring balance in national policies on controlled substances: Guidance for availability 
and accessibility of controlled medicines’ (hereinafter: WHO Policy Guidelines).4 These 
guidelines were updated at the start of the Access to Opioid Medication in Europe 
(ATOME) project; a project that aimed to improve access to medication in twelve 
Central and Eastern European countries with statistical evidence of very low morphine 
consumption per capita and no major ongoing initiatives to improve access to opioid 
medicines (Bulgaria, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Poland, Serbia, 
Slovakia, Slovenia and Turkey). Although the WHO Policy Guidelines give direction and 
include an assessment checklist, there is no practical assessment instrument available 
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with detailed information on potential barriers to evaluate legislation and regulations. 
The aim of this study was therefore twofold: (1) to develop and validate an assessment 
instrument for the systematic analysis of national legislation and regulations; and (2) to 
conduct a review using the instrument with the objective to identify potential legal and 
regulatory barriers to access to opioid medicines in eleven of the twelve countries 




Selection of national legislation and regulations 
The ATOME review of national legislation and regulations consisted of a two-step 
method: a quick scan of legislation24 provided a basis for a more thorough review. At the 
start of the ATOME project, country teams were composed based on their expertise and 
role in their country to ensure relevance to the project activities. These country teams 
included representatives from the national controlled substances authorities and 
national Ministries of Health, experts representing regulatory and law enforcement 
authorities and leading healthcare professionals and patient representatives. Within 
these country teams a legal expert was appointed to collaborate on the ATOME 
legislation review. Eleven of the twelve countries participated in the ATOME legislation 
review; the Poland ATOME country team decided not to participate and was therefore 
not included in this legislation review.  
Key experts in each country selected legislation concerning controlled 
substances and opioid medicines for the quick scan in the period the period March – 
November 2011. This quick scan consisted of the identification of obvious impediments 
in selected legal documents using eight of the 21 WHO Guidelines. In the framework of 
the more thorough review, the key experts in the selected countries were requested to 
update information about the legislation and provide information on forthcoming 
changes in the originally selected legislation. Initially collected and additional relevant 
legislation and regulations (collected until February 2013) were translated into English 
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by a translation agency (NOVA Language Services, Barcelona, Spain) if it was only 
available in the national language (see supplementary annex 1 for a full overview of 
selected and translated legislation and regulations). 
 
Analysis of national legislation and regulations 
In order to review legislation and regulations, a method was developed using an 
assessment instrument with potential barriers to access to opioid medicines focusing on 
nine different categories: prescribing; dispensing; manufacturing; usage; trade and 
distribution; affordability; penalties; language; and other (to include potential barriers 
that did not fit into one of the other categories). The assessment instrument was 
developed by authors JL, MHS and MV based on the WHO Policy Guidelines and 
additional literature regarding barriers to access.4,8,25–27 A selection of sub-categories 
(referred to as items) of potential barriers in the category prescribing and language is 
provided in Table 1. 
All relevant national legislation and regulations were analysed by one reviewer 
(author MV) and legal or regulatory provisions related to controlled substances and 
opioid medicines were selected for further review. These selected provisions were 
subsequently independently reviewed by three reviewers (authors JL, MHS and MV) 
using the assessment instrument and potential barriers to access to opioid medicines 
were identified. Differences of views between the reviewers regarding the identification 
of potential barriers were discussed until consensus was reached. Newly identified 
barriers were added to the assessment instrument and the reviewed legislation and 
regulations were checked retrospectively to complete the process.  
 
Validation of methods and results 
The reliability of the selection of provisions for further review by one reviewer 
(author MV) was validated by assessing the inter-rater reliability of the selection of 
provisions between two reviewers (authors MHS and MV) for a selected number of 
countries. The controlled substances law of three randomly selected countries (Hungary, 
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Serbia and Slovakia) was reviewed by the two reviewers and provisions were 
independently selected for further review. The selection by the two reviewers was 
compared using Cohen’s kappa statistics and was rated to be very good (kappa= 0.87). 
Following validation of the selection of provisions, the assessment instrument was 
piloted by all three reviewers to align the review process: selected provisions of one 
country (Greece) were analysed based on the assessment instrument and the three 
reviewers met to discuss differences of views which concerned general interpretation of 
the assessment instrument.  
Individual country reports containing the provisional results of the analysis of 
national legislation and regulations were disseminated to the ATOME country teams and 
discussed during the ATOME legislation review workshop in Utrecht, the Netherlands.28 
In total 14 representatives from nine of the eleven countries participating in the ATOME 
project (all countries except Bulgaria and Turkey) attended the meeting. Additionally, 
the country teams were invited to provide feedback in writing, using a feedback form 
that addressed several questions, including the correctness of the translation and the 
results (see supplementary annex 2). Feedback in writing was received from six of the 
eleven countries. Small changes were made to the results based on feedback received 
regarding small errors in translation, recent amendments in legislation or differences in 
interpretation of definitions and/or terminology. The changes did not lead to 
modification of the assessment instrument. 
 
Data analysis 
The total number of initially selected provisions was calculated per country and 
in total. Additionally, the total number of provisions that was considered to contain at 
least one potential barrier to access to opioid medicines was assessed in relation to the 
total number of provisions selected for review (per country and in total). Potential 
barriers were identified according to category and according to item within the 
categories (all categories except ‘language’). The presence of potential barriers in the 
category language was recorded qualitatively according to item to correct for language 
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repetitions. Individual differences between the countries were highlighted for the 
following items: limited prescription validity, special prescription forms required, 
multiple copies required, amount of controlled medicine to be prescribed is limited and 
daily dosage is limited.  
 
 Results 
Potential barriers identified 
In total, 925 provisions were initially selected for further review (author MV) 
varying from 35 provisions (Cyprus) to 144 provisions (Lithuania). A total of 86% of the 
initially selected provisions were considered to contain at least one potential barrier 
(including category ‘language’), ranging from 72% (Serbia) to 98% (Slovenia). Potential 
barriers to access were found in all eleven countries with the number of categories 
where items were found varying between six (Slovenia) to all (Bulgaria & Latvia) of the 
nine categories (Figure 1). In total, 778 potential barriers (excluding the category 
language) were identified in eleven countries, with the smallest number in Cyprus 
(n=22) and the largest number in Lithuania (n=128). Each country showed potential 
barriers in the categories ‘prescribing’, ‘dispensing’ and ‘usage’, while the total number 
of barriers in each category varied from 1 (several countries, several categories) to 49 
(Greece, prescribing) (Figure 1). Most barriers were identified for the prescribing and 
dispensing of opioid medicines, ranging from 5 (Cyprus) to 14 (Latvia) of the 20 items 
(see Table 2).  
 
Individual differences in barriers to access (categories prescribing and dispensing) 
Prescribing and dispensing restrictions and administrative requirements were 
the most common barriers identified in the categories ‘prescribing’ and ‘dispensing’, 
with individual differences in the level of impediment (Table 3). For example, the 
prescription validity varied from 5 days to 13 weeks, and special prescription forms were 
used in duplicate and triplicate. Restrictions regarding the total amount to be prescribed 
on a single prescription were identified in the legislation of several countries with 
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quantifications in the number of treatment days or by weight. Additional restrictions 
regarding the daily dosage were identified in the legislation of three countries. 
 
Examples of provisions identified 
Other potential barriers in the category of prescribing included requirements for 
a permit or license, restrictions regarding the authorisation to prescribe, administrative 
requirements and requirements for the storage of controlled medicines or prescription 
forms (see Table 2). Potential barriers in the category of dispensing included limitations 
regarding the pharmacies that are authorised to dispense, limitations on the dispensing 
on (designated) controlled medicines, administrative requirements, storage 
requirements and delivery restrictions. Besides the frequently reported prescribing and 
dispensing restrictions, potential barriers also include strict requirements for accessing 
education on controlled medicines, disproportional punitive sanctions for healthcare 
professionals, geographical restrictions to accessing opioid medicines, the violation of 
the privacy of patients and strict requirements for the storage of controlled medicines 
during international transportation (see Table 2). 
 
Language in legislation and regulations 
The legislation in all eleven countries referred to (patients with) dependence in a 
disrespectful manner (Table 4). Ten countries (all except Hungary) used incorrect 
definitions and/or unclear language in their legislation. These ten countries also had 
provisions in their legislation that do not make a clear distinction between medical use 
and illicit use or abuse. See Table 1 for examples of potential barriers in the category of 
language including an explanation.  
 
Discussion  
This study shows that the reviewed national legislation and regulations contain 
many potential barriers to access to opioid medicines that are indispensable for the 
management of cancer pain. Additionally, the study shows that all countries assessed 
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were considered to have language in their legislation that contributes to the 
stigmatisation of the use of opioid medicines. Most potential barriers concerned the 
prescribing and dispensing of opioid medicines, with individual differences in the level of 
impediment of several important items, such as limitations concerning the prescription 
validity, treatment duration and daily dosage. While legal and regulatory barriers to 
access to opioids have previously been identified by others, this is the first study 
showing detailed insight in the qualitative aspects of potential barriers by a systematic 
external review of legislation taken into account all elements in the pharmaceutical 
supply chain (from manufacturing to usage) and by using a newly developed assessment 
instrument based on the WHO Policy Guidelines4 that can be used in an universal 
manner by others.  
Other studies describing legal, regulatory or policy barriers to access to opioid 
medicines either conducted a survey18–21,25,29,30,22 or evaluated legislation and policies 
building on similar content as the WHO Policy Guidelines.31,27,26 Regulatory barriers to 
the accessibility of opioids for cancer pain in Central and Eastern Europe were previously 
reported by Cherny et al. based on surveys distributed among senior clinicians in the 
period 2007-2009.25 Results that were similar to the results of the current study were 
found concerning reported limitations on the treatment period and the requirement to 
use special forms or prescribe in multiple copies. Small differences between findings 
may be associated with the high level of detail in the present review and the availability 
of information on recent amendments. Different results were seen regarding the use of 
stigmatising language in legislation, which may be the result of underreporting by the 
survey’s respondents. A worldwide follow up of the European survey by Cherny et al. 
revealed that regulatory barriers and restricted formularies also play an important role 
in inadequate access to opioid medicines for the treatment of cancer pain in Africa, Asia, 
Latin America, the Caribbean and the Middle East, affecting hundreds of millions of 
patients.18–21,29,30 While the focus of both abovementioned surveys – and most other 
studies – was restricted to a predefined subset of potential barriers, the scope of our 
study allowed for identification of every potential barrier encountered by systematically 
11 
 
reviewing all selected legislation. Due to this broad and systematic approach potential 
hurdles to accessing opioids were also located in less obvious areas. Additional research 
is needed to refine the assessment instrument and to assess the intention of the 
respective legal provisions and their impact on access in clinical practice.  
Several limitations of the present external review of legislation should be 
mentioned. First of all, legal and regulatory data were analysed based on the selection 
made by key experts in the specific countries and in many cases after translation into 
English. Both incorrect translation and incomplete selection of documents may have 
caused incomplete or incorrect reporting of potential barriers. By training and guidance 
of carefully selected key experts and by following a two-step method with an additional 
update of legal and regulatory text, the omission of data was minimised. Inconsistencies 
in translation were reduced as much as possible by working with a professional 
translation agency, specialised in the area of law and health and by dissemination of the 
results to the ATOME country teams with the explicit request to provide feedback on 
errors in translation. Secondly, as the methods of this study comprised an analysis of 
legal text, inevitably variation of interpretation may occur. By involving three reviewers 
and by determining the general interpretation of the assessment instrument the chance 
of divergent interpretations has been minimised.  
This external review of national legislation was not only shown to be useful for 
the identification of potential barriers, but the detailed level of information on these 
potential barriers has led to specific recommendations for improvement as a part of the 
ATOME project. Several participating countries have already implemented some of 
these recommendations. For example in Lithuania, the total number of special 
prescription forms physicians are allowed to receive has been doubled from 10 to 20 
forms. In Estonia, the requirement for pharmacies to obtain a special permit which 
makes them authorised to dispense controlled medicines was removed. Due to this 
requirement, pharmacies were reluctant to apply for a license with the result that 
patients had difficulties identifying a pharmacy that could dispense their opioid 
medicines.32 Although all these examples are considered to contribute to better access 
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to opioids for patients, the impact of these revisions on clinical practice has not been 
assessed and therefore remains unknown. Additional research is recommended to 
assess the impact of lifting potential barriers in these countries. Additional research is 
also needed to assess the level of impact of different types of barriers as it can be 
assumed that some types of barriers are more likely to influence access than others. 
Finally, scientific data are also needed in a broader context to gain insight in how a 
restrictive control system exerts impact on access to opioid analgesics in comparison to 
a very liberal system. So far only anecdotal evidence exists showing a direct correlation 
between strict prescribing or dispensing requirements and patients being denied 
adequate pain treatment.33,34 Society would benefit from solid data showing how we 
can achieve less drug related risks and better clinical outcomes for patients with 
moderate to severe cancer pain by optimising legislation and regulations.  
In conclusion, the potential barriers identified by this external review of 
national legislation give rise to a critical national review and revision of provisions that 
impede access to opioid medicines for patients with cancer pain in a way that is 
disproportional to their (intended) benefit for the prevention of abuse and diversion. To 
provide a legal framework that focuses on access to opioid medication with maximum 
health outcome, these revisions should take place in consultation with healthcare 
professionals and patient organisations. Several countries participating in the ATOME 
project are already in the process of revising legislation and implementing 
recommendations for improvement, bringing patients in medical need one step closer 
towards adequate access to opioid medicines.  
 
Search strategy and selection criteria 
A literature search was done in PubMed and Google Scholar to identify relevant 
publications published in English language. We used the following keywords in titles or 
abstracts: “barriers” OR “impediment’s” combined with the search terms “legislation” 
OR “legal” OR “regulation(s)” combined with the search terms “opioids” OR “opioid 
medicines” OR “opioid analgesic(s)” OR “narcotic drug(s)”. The search was not limited to 
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year of publication. The relevance of the publications was determined by a preliminary 
review of the abstracts. In addition to the electronic search using keywords, the 
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Figure 1: total number of potential barriers identified per country according to category (except category language) 
 





POTENTIAL BARRIER FOR EXAMPLE IF… 
 
RELATES TO WHO 
POLICY GUIDELINE  
 
EXAMPLES: POTENTIAL BARRIERS IDENTIFIED IN LEGISLATION 
authorisation to prescribe 
is restricted 
…. the competence to prescribe controlled medicines is 
restricted to a limited number of medical specialists 
(such as oncologists only) and other appropriately 
trained and qualified physicians are not authorised to 
prescribe controlled medicines. 
GUIDELINE 11 “If it appears that a patient will need to use a controlled 
substance for longer than 30 days or will need it repeatedly, 
the family practitioner only shall be authorized to prescribe it 
(…).”35 
special permit/ license 
required for prescribing 
…only designated institutions are allowed to prescribe 
controlled medicines or if a special permit or license is 
required for prescribing controlled medicines, in 
particular if the application procedure is complex and if 
high fees apply to applicants. 
GUIDELINE 11  “(…) In cases of cancer patients, and only after a relevant 
permit by the health department of the local prefectural 
administration, the physician can dispense a special narcotics 
prescription for an amount that exceeds the maximum daily 
dose for a five-day (5) treatment. The local prefectural 
administration’s permit is valid for one (1) month.”36  
special prescription forms 
required / prescribing in 
multiple copies required 
…if special forms or multiple copies are required, in 
particular if these special prescription forms are not 
readily available and/or are not free of charge and/or 
entail many administrative requirements for healthcare 
professionals, in particular if unintended violation of 
these administrative requirements may result in severe 
sanctions. 
GUIDELINE 9 “The persons involved in activities related to narcotic 
substances shall purchase the special forms from the regional 
healthcares centres.”37 
“The size of the original copy of a prescription for narcotic 
drugs is 127×158 mm, three sheets. The pharmacy shall have 
the original prescription and one copy thereof and the health 
care provider shall have one copy.“38 
limited prescription 
validity 
…patients in need of controlled medicines - especially 
patients with chronic conditions – have to visit the 
physician and pharmacy frequently, in particular if 
additional rules aggravating the impact apply, such as 
rules that limit the total amount of controlled medicine 
to be prescribed. 
GUIDELINE 9 “Prescriptions issued by physicians are valid for the following 
periods of time: (…) Narcotic drugs - 5 days, including the day 
the prescription was issued; (...)”39 
amount of controlled ...patients who require medical treatment with GUIDELINE 9 “If there is no other way to suppress the pain, it shall be 
allowed to exceed 3 times the norms, indicated in the table of 
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medicine to be prescribed 
is limited 
controlled medicines for a longer period have to visit 
the physician and pharmacy frequently, in particular if in 
addition to this potential barrier the validity of a 
medical prescription for controlled medicines is limited. 
paragraph 31, indicating in the prescription “Special 
assignment" and confirming it additionally by affixing the 
physician's signature and personal stamp.”40  
 
daily dosage is limited  …the maximum dosage is lower than evidence based 
medical treatment guidelines advice and/or individual 
patient needs may require higher dosages.  
GUIDELINE 11 “Per day of treatment, a general practitioner may only 
prescribe one tenth of the quantities specified in the previous 
paragraph per individual patient, while the total quantity of a 
medicinal product prescribed may not exceed the quantity 
specified in the previous paragraph.”41 
no clear distinction 
between medical use and 
illicit use/abuse 
…the language used in legislation does not provide a 
clear distinction between medical use and illicit 
use/abuse and as a result causes confusion and/or fear 
for the use of opioid medicines in medical practice, in 
particular when severe sanctions are involved for 
unintended violations. 
GUIDELINE 10 “Preventive measures (…) in order to reduce the supply of 
narcotic and psychotropic substances (…).”42 
 
“(…) when the use of narcotic and psychotropic substances 
was the main reason causing death.”43 
incorrect definitions are 
used 
…the language used contains biased definitions or 
presuppositions regarding the nature, effect, or rational 
use of opioids that may encourage distorted knowledge 
or assumptions and/or may cause fear for the use of 
opioid medicines in medical practice, in particular when 
severe sanctions are involved for unintended violations. 
GUIDELINE 10 “According to their legal definition, narcotic drugs are artificial 
or natural substances that act on the central nervous system 
and cause the individual in question to develop an addiction to 
them.”44  
unclear language is used …the language used contains wording and/or 
terminology that leave space for interpretation (for 
example, the use of vague adjectives) and cause 
confusion and/or cause fear for the use of opioid 
medicines in medical practice, in particular when severe 
sanctions are involved for unintended violations. 
GUIDELINE 10 “Medicines containing narcotic drugs can be prescribed only if 
their use is necessary and if they are marketed under the Law 
on production and marketing of medicines.”45 
controlled medicines are 
referred to as dangerous, 
toxic or addictive drugs 
…the language used contributes to the stigmatisation of 
opioid medicines and/or causes fear for the use of 
opioid medicines in medical practice. 
GUIDELINE 10 “For medical products, containing intoxicating substances, the 




















authorisation to prescribe is 
restricted 
 
          
permit/license required for 
prescribing  
           
special prescription forms 
required 
           
multiple copies required            
limited prescription validity            
amount of controlled 
medicine to be prescribed is 
limited 
           
daily dosage is limited            
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prescribing of (designated) 
controlled medicines is 
limited 




           
amount of controlled 
medicine to be prescribe is 
limited to complete 
package units 
           
patient supervision 
requirements for prescriber 







limitations on dispensing 
privileges: special license 
required 
           
limitations on dispensing 
privileges: special license 
pharmacy / designated 
pharmacies 
           
limitations on the 
dispensing of (designated) 
controlled medicines 
           
administrative 
requirements for dispensing 
           
                                                 
1 Requirements that increase the administrative burden and may cause medical practitioners to be unable or reluctant to treat patients with controlled medicines and do not 
solely concern any of the other categories. For example, the requirement that physicians are allowed to receive a limited number of prescription forms which need to be stored 
in a designated safe. 
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requirements for storage 
(dispensing)  
           
delivery restrictions of 
controlled medicines  
           
limited prescriptions 
validity (dispensing) 
           
amount of controlled 
medicine to be dispensed is 
limited 
           
dispensing in emergency 
situations /correction of 
small errors restricted 





possession of controlled 
medicines by patients 
restricted 
           
geographical restrictions            
continuation of treatment 
restricted 
           
access to pain treatment for 
HIV patients or patients 
with (a history of) 
dependence 
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strict requirements for 
accessing dependence 
treatment 
           
administrative 
requirements for receiving 
controlled medicines 
           
limitations for certain 
patient groups 
           













requirements for storage 
(trade and distribution)2 
           
administrative 
requirements for trade and 
distribution3 
           
requirements for 
transportation4 
           
                                                 
2 Requirements that may cause legal entities to be unable or reluctant to store controlled medicines due to the high costs of the security measures. For example, requirements 
regarding the safes, security systems or requirements that dictate the thickness of the bars in the windows. 
3 Requirements that increase the administrative burden and may cause legal entities to be unable or reluctant to trade in controlled medicines. For example, very strict 
timelines for completing the application for an import or export license, in particular if the information requested cannot be easily retrieved. 
4 Requirements that may cause legal entities to be unable or reluctant to transport controlled medicines due to the high costs of these security measures. For example, the 
requirement that controlled medicines can only be transported in a vehicle that is equipped with metal containers with special security locks.  
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trade and distribution 
limited to designated 
parties 










requirements for storage 
(manufacturing)5 












 costs of controlled 
medicines7 
 







punitive sanctions for 
healthcare professionals 
           
punitive sanctions (other)            
punitive sanctions for 
patients 
           
                                                 
5 Requirements that may cause legal entities involved in manufacturing to be unable or reluctant to store controlled medicines due to the high costs of the security measures. 
For example, requirements regarding the safes, security systems or requirements that dictate the thickness of the bars in the windows. 
6 Requirements that increase the administrative burden and may cause legal entities to be unable or reluctant to manufacture controlled medicines. For example, very strict 
timelines for completing the application to receive a permit for manufacturing opioid medicines, in particular if the information requested cannot be easily retrieved. 




punitive sanctions for 
persons involved in 
manufacturing / trade and 
distribution 





medical activities restricted8             
violation of privacy             
requirements for the 
destruction of controlled 
medicines9 
           
storage requirements 
(other)10  
           
administrative 
requirements (other) 
           
limited access to education             
 
                                                 
8 Restrictions that have an impact on medical activities and do not solely concern any of the other categories. For example, specific requirements for healthcare institutions 
providing treatment with controlled medicines. 
9 Requirements for the destruction of controlled medicines that may deter legal entities or healthcare professionals from working with controlled medicines. For example, 
complex reporting requirements for the disposal of controlled medicines or the requirement that unusable controlled medicines can only be destroyed in the presence of a 
representative from the government.  





Table 3: Individual differences in the level of impediment of potential barriers (category prescribing) 
country limited prescription validity 
multiple copies or special  
forms required 
total amount or treatment  
period limited 
maximum daily dosage 
Bulgaria 7 days from the date of 
issuance 
three copies: original and two 
copies in different colours (yellow 
and green) printed on carbon paper 
30 days not identified 
Cyprus 13 weeks  not identified 13 weeks not identified 
Estonia 30 days (non-controlled 
medicines 60 days) 
three copies, 127 x 158 mm sheets 
printed in green on red self-copying 
paper with 80 mm binding holes on 
the left, a security print on the 
margins and a 7-digit number in 
black in the upper left-hand corner  
30 days  not identified 
Greece not identified two copies, serial numbered 
containing a double red line on the 
top right side and the text ‘special 
narcotic drug prescription’ 
the amount to be dispensed on a single 
prescription varies: 1 day (substances listed 
in Tables B & C); 5 days 
(dextropropoxyphene, methyphenidate, 
pentazocine); 15 days (fentanyl 
transdermal patches); 30 days (treatment 
of patients with cancer, provide that a 
permit is granted: permit valid 1 month). 
maximum daily dosages in 
legislation, e.g. morphine 50 
mg; maximum daily dosages 
can be exceeded for the 
treatment of patients with 
cancer, during maximum 5 
days, provided that a permit is 
granted 
Hungary 5 days 
  
not identified 15 days / 30 days (prescribed by general 
practitioner) / 90 days (prescribed by 
general practitioner for patients travelling); 
repeat prescription allowed by general 
















Latvia 30 days (non-controlled 
medicines 90 days) 
margins and part to be completed 
by the pharmacy is coloured in light 
red 
maximum amounts to be prescribed in 
Annex 5 of Regulation No175; treatment 
period limited to 14 days (buprenorphine) / 
30 days / 90 days (only narcotic analgesic 
products prescribed by a psychiatrist, 
narcologist, neurologist or family doctor) 
daily dosage of buprenorphine 
legally restricted. 
Lithuania 5 days, including the day of 
issuance.  
blank form 2 for ‘narcotic 
medicines’ and blank form 3 for 
compensated ‘narcotic medicines’ 
maximum amounts to be prescribed for a 
patient on a single occasion, e.g. morphine 
2 g. total amount limited to a 7 day 
treatment course; transdermal: 30 days 
not identified 
Serbia 7 days from the date of 
issuance 
two copies, serial numbered, with 
the second copy marked ‘copy’. 
maximum amounts to be prescribed for a 
patient on a single occasion, e.g. 0.2g 
morphine; amount limited to treatment 
period of 30 days; for the treatment of 
malignant diseases: duration of treatment 
limited to 14 days 
not identified 
Slovakia 5 days three copies, forms marked with 
blue diagonal stripe 
30 days; no repeat prescriptions allowed.  not identified 
Slovenia 5 days, excluding the day of 
issuance 
two copies, serial numbered, with 
the second copy marked ‘copy’. 
30 days; no repeat prescriptions allowed; 
maximum amounts to be prescribed 
specified in legislation 
daily dosage may not exceed 
1/10 of maximum amounts 
specified 
Turkey not identified three copies, serial numbered, 
carbon paper in green 
(psychotropic substances) or red 
(narcotic substances)  
maximum amounts to be prescribed on a 
single prescription specified in legislation, 









Table 4: Potential barriers identified in the category ‘language’ in legislation 
IITEM/COUNTRY BULGARIA CYPRUS ESTONIA GREECE HUNGARY LATVIA LITHUANIA SERBIA SLOVAKIA SLOVENIA TURKEY 
reference to (persons 
with) dependence in a 
disrespectful manner in 
legislation (e.g. addicts or 
addiction) 
 
          
incorrect definitions 
and/or unclear language 
in legislation 
           
absence of a clear 
distinction between 
medical use and illicit use 
or abuse in legislation 
           
reference to controlled 
medicines as dangerous, 
toxic or addictive drugs in 
legislation 
           
 
 












controlled substances legislation 
(general) 
medicinal products legislation legislation concerning healthcare 








Law for Control over the Narcotic 




Law on the Medicinal Products in 
Human Medicine (2007)  
 
 
Ordinance No. 34/2005 on the 
procedure for state budget 
funding of the treatment of 
Bulgarian citizens with regard to 
diseases beyond the scope of 
compulsory health insurance 
Ordinance No. 24/2000 on the 
rules and procedures for the 
implementation of substitution 
and maintenance programs for 
the reduction of health damage 
for persons addicted to narcotic 
drugs 
 
Ordinance No. 21/2000 on the 
requirements for documentation 
and reporting during activities 
involving narcotic substances and 
their preparations 
 
Ordinance No 4/2009 on the 
rules and procedures for the 









The Narcotic Drugs and 
Psychotropic Substances Law 
1977, incorporating amendments 
up to 1992.  
    
The Narcotic Drugs and 
Psychotropic Substances 
Regulations 1979, incorporating 
amendments up to 1987. 
    
The Narcotic Drugs and 
Psychotropic Substances 
(Amendment) Regulations of 




The Narcotic Drugs and 
Psychotropic Substances 
(Amendment) Law 91(I) of 2003 
    
The Narcotic Drugs and 
Psychotropic Substances 
(Amendment) Decree of 1996 
(P.I. 4/96) 
    
The Narcotic Drugs and 
Psychotropic Substances 
(Amendment) Law 24(I) of 2010 






Act on Narcotic Drugs and 
Psychotropic Substances and 
Precursors thereof (passed 11 
June 1997, RT I 1997, 52, 834, 
entered into force 1 November 
1997) 
Medicinal Products Act 
(Passed 16 December 2004 (RT I 
2005, 2, 4)Entry into force 1 
March 2005) 
Health Insurance Act  The Conditions and Procedure 
for the Import and Export, 
Carrying for Personal Use and 
Sending by Post of Goods 
Requiring Special Authorisation 
of the State Agency of 
Medicines, the Forms of Special 
Authorisations and the List of 
Goods Requiring Special 
Authorisation of the State 
Agency of Medicines  
(Passed with Regulation No. 31 
on 18.02.2005, RTL 2005, 23, 





Conditions and Procedure for 
Handling of Narcotic Drugs and 
Psychotropic Substances for 
Medical and Research Purposes, 
and Conditions and Procedure for 
Maintaining Records and 
Reporting in that Area and 
Schedules of Narcotic Drugs and 
Psychotropic Substances 
(Regulation No. 73 of the 
Minister of Social Affairs of 18 
May 2005 (RTL 2005, 57, 
807),entered into force 5 July 
2005) 
 
The Conditions and Procedure for 
the Issue of Prescriptions for 
Medicinal Products and for the 
Dispensing of Medicinal Products 
by Pharmacies and the Format of 
Prescriptions  
(Approved by Regulation No. 30 
of the Minister of Social Affairs of 
18 February 2005 (RTL 2005, 23, 
315), entered into force 
01.03.2005) 
 
   
 Conditions and Procedure for 
Wholesale Distribution of 
Medicinal Products 
(Approved by Regulation No. 27 
of the Minister of Social Affairs of 
17 February 2005 (RTL2 2005, 22, 
308), entered into force 
01.03.2005) 





Act No. 3459/2006 on Legal 
Codes for Drugs 
    
Presidential Decree 148/2007 on 
the codification of the provisions 
stipulated in the regulatory 
decrees and ministerial orders 
regarding national legislation on 




Ministerial Order No. 
Α6b/6543/15-07-1988 on the 
definition of terms and 
conditions of the availability of 
substances provided for in 
article 4 of Act No. 1729/1987 






Government Decree 162/2003. 
(X. 16.) On cultivation, 
distribution and use of plants 
suitable for the production of 
narcotic drugs 
 
Act XCV of 2005 on Medicinal 
Products for Human Use and 
on the Amendment of Other 
Laws Regulating the 
Pharmaceutical Market 
 
Act CLIV of 1997 on Health Joint Decree 42/2008 (XI. 14.) 
EüM-SZMM of the Minister of 
Health and the Minister for 
Social Affairs and Labour on the 
rules of treatment for narcotic 
drug dependence of other 
services attending to drug use 
and of prevention and 
counselling service 
 
Government Decree No. 66/2012 
(2nd of April) on the activities that 
may be conducted with narcotic 
drugs, psychotropic substances 
and new psychoactive 
substances, and on the inclusion 
of such substances in schedules, 
and on the amendment of such 
schedules 
 
ESzCsM (Ministry of Health, 
Social and Family Affairs) Decree 
44/2004 (IV. 28) on prescribing 
and dispensing medicinal 
products for human use. 
   
EüM (Ministry of Health) Decree 
43/2005 (X.15.) on the system 
for physician’s prescriptions, 
trading in pharmacies, 
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consumption, recording and 
storage at healthcare providers 
of medicinal products classified 





National Law On Procedures for 
the Legal Trade of Narcotic and 
Psychotropic Substances and 





Cabinet of Ministers 23/03/2010 
Regulations No 288 “Regulations 
Regarding Operating of 
Pharmacies” 
Policy document Oncologic 
diseases control program for 
years 2009-2015 
Programme for Limiting the 
Spread of Human 
Immunodeficiency Virus (HIV) for 
2009–2013, approved by Decree 
of Cabinet of Ministers No 437 of 
30/06/2009 
 
Cabinet of Ministers 8/11/2005 
Regulations No 847 “Regulations 
regarding Narcotic Substances, 
Psychotropic Substances and 
Precursors to be controlled in 
Latvia” (including separate 
amendments 12/05/2009 and 
3/11/2009) 
Cabinet of Ministers 26/06/2007 
Regulations No 416 “Procedures 
regarding the Distribution and 
Quality Control of Medicinal 
Products” (including separate 
amendment on 27/07/2010). 
Cabinet of Ministers 31/10/2006 
Regulations No 899 “Procedures 
for the Reimbursement of 
Expenditures for the Acquisition 
of Medicinal Products and 
Medicinal Devices Intended for 
Out-patient Medical Treatment” 
 
Cabinet of Ministers 24/09/2002 
Regulations No 429 “Procedures 
for the Treatment of Patients 
Addicted to Alcohol, Narcotics, 
Psychotropic and Toxic 
Substances”  
 
Cabinet of Ministers 17/06/2008 
Regulations No 441 “Procedures 
for the Purchase, Receipt, 
Storage, Distribution, 
Dispensation, Accounting and 
Destruction of Narcotic and 
Psychotropic Substances and 
Medicinal Products in 
Manufacturing of Medicinal 
Products and Veterinary 
Medicinal Products, at Drug and 
Veterinary Drug Wholesalers and 
Medical Treatment Law Cabinet of Ministers 19/12/2006 
Regulations No 1046 
“Procedures for organization 





Cabinet of Ministers 13/08/1996 
Regulations No 327 “Regulations 
on the Transit of Narcotic and 
Psychotropic Substances and 
Drugs” (including separate 
amendments 24/07/2007 and 
04/08/1998) 
Cabinet of Ministers 08/03/2005 
Regulations No 175 ”Regulations 
for Manufacture and Storage of 
Prescription Forms, as well as 
Writing out and Storage 
Prescriptions” (Including separate 
amendment on 12/04/2011 of 
Regulations No 175) 
   
Cabinet of Ministers 21/04/2008 
Regulations No 293 “Procedures 
by which a Permit for the 
Utilisation of Plants, Substances 
and Medicinal Products Included 
in Schedules I, II or III of Narcotic 
Substances, Psychotropic 
Substances and Precursors 
Controlled in Latvia for Medical 
and Veterinary Medical Scientific 
Research, Specification of 
Physical and Chemical Properties 
or for Educational Purposes is 
Issued, Suspended and Revoked” 
Cabinet of Ministers 27/03/2007 
Regulations No 220 “Procedures 
for Acquisition, Storage, Use, 
Registration and Disposal of 
Medicinal Products in Medical 
Treatment Institutions and Social 
Care Institutions” (Including 
separate amendments on 
Regulations 220 on 08/04/2008, 
10/03/2009, 31/08/2010 and 
25/01/2011) 







Republic of Lithuania Law on the 
Control of Narcotic and 
Psychotropic Substances 
Order of the Minister of Health 
of the Republic of Lithuania No. 
112 of 8 March 2002 “On 
Medical Prescriptions and 
Disbursement (Sale) of 
Medicines” (Published: Official 
Gazette Valstybės Žinios, 
16/03/2002, No. 28, Publication 
No. 1013). 
 Order No. 204 of the Minister of 
Health of 3 May 2002 “On the 
Approval of Standards for 
Treatment and Rehabilitation of 
Dependency Diseases” (Official 





Republic of Lithuania Law on the 
Control of Precursors of Narcotic 
Drugs and Psychotropic 
Substances 
  Order No. V-653 of the Minister 
of Health of the Republic of 
Lithuania of 6 August 2007 “On 
the Approval of Procedure 
Descriptions for Assigning 
Substitution Treatment and its 
Application to Treat Opiate 
Dependency, and Prescription, 
Disbursement, Storage and 
Accounting of Substitution 
Opiate Medicinal Preparations in 
Personal Health Care 
Institutions” 
 
Government of the Republic of 
Lithuanian Resolution regarding 
the approval of regulations of 
issuing licenses to produce, 
import and export narcotic and 
psychotropic substances, and to 
engage in their wholesale and 
retail trade (Last amended on 
2011 July 22: No. 887, 
13.07.2011, Zin. (Official 
Gazette), 2011, No. 93-4403 
(21.07.2011)) 
    
Republic of Lithuania 
Government Resolution No. 591 
of 30 May 2005 “On the 
Approval of the Description of 
the Procedure for Monitoring 
the Use of Narcotic and 
Psychotropic Substances, 
Consequences thereof, the 
Circulation of the Precursors of 
Narcotic and Psychotropic 




Republic of Lithuania 
Government Resolution No. 221 
of 9 March 2006 “On the 
Approval of the Regulations for 
the Licensing of Activities 
Involving the Precursors of 
Narcotic and Psychotropic 
Substances, Registration of the 
Place Thereof, Issuance of 
Import and Export 
Authorisations, and Control of 
such Activities” 
    
Order No. 275 of the Minister of 
Health of the Republic of 
Lithuania of 24 May 2000 “On 
the Premises for Keeping 
Narcotic and Psychotropic 
Medicines and Medicinal 
Substances in Hospital 
Pharmacies“ 
    
Order of the Minister of Health 
of the Republic of Lithuania No. 
V-2 of 23 April 2003 “On 
Recommendations for 
Determining Small, Large and 
Very Large Amount of Narcotic 
and Psychotropic Substances” 
(Published: Official Gazette 
Valstybės Žinios, 30/04/200, No. 
41, Publication No. 1899). 
    
Order No. 342/482 of several 
institutions (Minister of Health 
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of the Republic of Lithuania and 
Minister of the Interior of the 
Republic of Lithuania) of 25 
August 1998 “On the Approval 
of the Description of Special 
Requirements for Premises 
where Narcotic and/or 
Psychotropic Substances of 
Schedules II and III are Produced 
and Stored, their Wholesale and 
Retail Sale Takes Place” 
(Published: Official Gazette 
Valstybės Žinios, 02/09/1998, 
No. 77, Publication No. 2195; 
Official Gazette Valstybės Žinios, 
16/10/2008, No. 119, 
Publication No. 4521). 
Order No. 409 of the Minister of 
Health of the Republic of 
Lithuania of 25 July 2001 “On 
the Ensuring of Control of 
Import and Export of Narcotic 
and Psychotropic Medicines and 
Medicinal Substances” 
(Published: Official Gazette 
Valstybės Žinios, 01/08/2001, 
No. 66, Publication No. 2429; 
Official Gazette Valstybės Žinios, 
14/07/2005, No. 85, Publication 
No. 3184). 
    
Order No. V-138 of the Minister 
of Health of the Republic of 
Lithuania of 2 March 2007 “On 
the Approval of the Description 
of Procedure for Issuance of the 
    
41 
 
Certificate for Transportation of 
Narcotic and/or Psychotropic 
Substances for Personal Usage 
for Medical Purposes” 
(Published: Official Gazette 
Valstybės Žinios, 10/03/2007, 
No. 30, Publication No. 1109). 
Order No. 294 of the Minister of 
Health of the Republic of 
Lithuania of 4 June 1998 “On the 
Procedure of Keeping Narcotic 
and Psychotropic Medicines and 
Medicinal Substances in Means 
of International Transportation” 
(Published: Official Gazette 
Valstybės Žinios, 19/06/1998, 
No. 56, Publication No. 1568). 





Law on psychoactive controlled 
substances 
 
Rulebook on the prescription 
and dispensing of medicines 
(FRY Official Gazette No. 16/94, 
22/97, 52/02) 
 
Rulebook on contents and scope 
of health care from compulsory 
health insurance and on 
participation for 2012 
 The criminal code 
 Rulebook on advertising of 
medicines and medical devices 
 
Draft National Palliative Care 
Strategy 
 




 Law on medicines and medical 
devices (Official Gazette no 
30/10) 
 
Action Plan for Palliative Care in 








Act. N. 139/1998 on Narcotic 
Drugs, Psychotropic Substances 
and Preparations  
Act. N. 140/1998 on medicinal 
products and medical devices, 
replaced by Act. N. 362/2011 on 
medicinal products and medical 
devices11 
Regulation regarding standards 
for diagnosis and treatment 
Vocational guidance No. 
M/0509/2003 on the standards 
for the diagnosis and treatment 
of drug dependencies 
 
Decree 158/2010 of 23 March 
2010 of the Ministry of Health 
laying down formal 
requirements for the book of 
narcotic substances and keeping 
records of narcotic substances 
proving receipt and dispensing 
of narcotic and psychotropic 
substances 
Act. N. 147/2001 on Advertising 
of Medicinal Products  







Order on the Promulgation of the 
Prevention of the Use of Illicit 
Drugs and Dealing with 
consumers of Illicit Drugs Act 
Rules on classifying, prescribing 
and dispensing medicinal 
products for human use 
Law on Health Care and Health 
Insurance 
 The constitution of the Republic 
of Slovenia 
Production of and Trade in Illicit 
Drugs Act 
 Act(s) Amending the Health Care 
and Health Insurance Act 
  
                                                 
11 Although Act. N. 140/1998 has been replaced by Act. N. 362/2011, no important changes have been made to the parts that were indicated as relevant by the national 
counterpart. Therefore, Act. N. 140/1998 has been (partly) reviewed.  
43 
 
Decree on the Scheduling of Illicit 
Drugs 
 General agreement 2010   
Rules Governing the Procedures 
for the Issue of Licences for Illicit 
Drugs Marketing 
 Resolution on National plan of 
health care 2008-2013 
  
Rules on Method And Form of 
Record-keeping and of Reports 
on Illicit Drugs 
    
Rules on Technical And Sanitary 
Conditions And on the Method 
of Insurance of Premices for 
Storage and Dispensing of Illicit 
Drugs from Groups I and II 





Law No.2313 (12/06/1933) on 
Supervision of Narcotic Drug  
Pharmaceuticals Track&Trace 
System 
 Regulation No. 25375 on 
Substance Abuse Treatment 
Centres (16/03/2004) 
Law No.984 (12/03/1927) on 
stores where toxic and effective 
chemical substances used in 
pharmaceutical businesses and 
in vocational & agriculture 
businesses are sold 
Circular No.5725 (26/01/1984) 
on submitting consumables of 
controlled substances and 
pharmaceutical preparations  
Law No.1262 (26/05/1928) on 
the Pharmaceuticals and 
Medicinal products 
   
Circular No.5768 (29/05/1985) 
on the prescription of narcotics, 
controlled drugs and 
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Feedback document: ATOME legislation review country report, country X 
Date  
Is the reviewed legislation (paragraph 6.1) still valid? If not, please specify…. 
Are the translations correct? This is even more important for the translation of provisions that are identified 
as potential barriers in the category ‘language’. Please specify…. 
Are there any doubts or disagreements regarding the identification of potential barriers? Please specify…. 
Are there potential legal or regulatory barriers missing? Please specify… 
Are there any doubts or disagreements regarding the proposed recommendations? Please specify… 
Are there any recommendations missing that should be added? Please specify… 
Are there any other questions, comments or concerns we should take into account? Please specify… 
  
